<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>GIDS Research Radar · Hebei, China</title>
  <link>https://globalinfectiousdisease.com/research/</link>
  <description>Published infectious-disease literature filtered to Hebei, China.</description>
  <language>en</language>
  <atom:link href="https://globalinfectiousdisease.com/research/rss/countries/cn-he.xml" rel="self" type="application/rss+xml" />
  <lastBuildDate>Sat, 07 Nov 2026 03:45:11 GMT</lastBuildDate>
  <item>
    <title>Surveillance of avian influenza viruses in Hebei Province of China from 2021 to 2023: Identification of a novel reassortant H3N3</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1016-j-jinf-2024-106240-37ef0d8a/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1016-j-jinf-2024-106240-37ef0d8a/</guid>
    <pubDate>Tue, 01 Oct 2024 00:00:00 GMT</pubDate>
    <description>Continuous evolution of avian influenza in local wild waterfowl warrants sustained risk assessment, given rare human infections and pandemic potential noted in the background.</description>
    <category>Influenza</category>
    <category>Surveillance</category>
    <category>Transmission dynamics</category>
    <category>Climate and environment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-21-00681-2-6171133c/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-21-00681-2-6171133c/</guid>
    <pubDate>Fri, 01 Apr 2022 00:00:00 GMT</pubDate>
    <description>Findings support that a booster at 8 months can restore waned anti-SARS-CoV-2 immunity in adults receiving the inactivated vaccine.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Vaccine safety</category>
    <category>Randomised controlled trial</category>
  </item>
</channel>
</rss>
